Lotus OTCs boost retail sales
This article was originally published in The Tan Sheet
Executive Summary
Increased distribution to OTC drug outlets in Beijing helps Lotus Pharmaceuticals grow net retail revenue 52.2 percent to $3.3 million in the Chinese firm's fiscal 2010 first quarter. OTC drugs are a new venture for Lotus, which expects to expand the business with a recently recruited sales team and a storage and distribution facility under construction, the company said May 14. Overall net revenues, largely generated by Lotus' wholesale Rx segment, increased 26.4 percent to $14.9 million in the first quarter 2010. Net income rose 36.1 percent to $4.9 million
You may also be interested in...
Lotus expands OTC business
The Beijing-based pharma says it signed OTC drug purchase agreements with 11 manufacturers during its second quarter, when retail revenues grew 123 percent to $6.2 million, thanks largely to OTC direct sales to Beijing outlets. Lotus Pharmaceuticals only recently entered the OTC business with a new sales team and an under-construction distribution facility (1"The Tan Sheet" May 24, 2010, In Brief). The firm said Aug. 16 its overall net revenue climbed 19.4 percent to $12.7 million in the April-June period and 23.6 percent to $24.2 million in the half
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.